Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

Study:

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)

Rationale:

n/a

Purpose:

This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with Stage 4 Chronic Kidney Disease (CKD) and type 2 diabetes receiving standard of care.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Renal Insufficiency, Chronic
Diabetes Mellitus, Type 2		 Drug: Placebo
Drug: Bardoxolone Methyl: 20 mg		 Phase 3

Verified by Reata Pharmaceuticals, Inc. October, 2012

Sponsored by: Reata Pharmaceuticals, Inc.
Information provided by: Reata Pharmaceuticals, Inc.
ClinicalTrials.gov identifier: NCT01351675

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.